TW200618795A - Amorphous atorvastatin calcium - Google Patents
Amorphous atorvastatin calciumInfo
- Publication number
- TW200618795A TW200618795A TW094134218A TW94134218A TW200618795A TW 200618795 A TW200618795 A TW 200618795A TW 094134218 A TW094134218 A TW 094134218A TW 94134218 A TW94134218 A TW 94134218A TW 200618795 A TW200618795 A TW 200618795A
- Authority
- TW
- Taiwan
- Prior art keywords
- atorvastatin calcium
- amorphous atorvastatin
- amorphous
- stability
- calcium
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 3
- 229960001770 atorvastatin calcium Drugs 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61457804P | 2004-09-30 | 2004-09-30 | |
| IN715CH2005 | 2005-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200618795A true TW200618795A (en) | 2006-06-16 |
Family
ID=36143063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094134218A TW200618795A (en) | 2004-09-30 | 2005-09-30 | Amorphous atorvastatin calcium |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080009540A1 (enExample) |
| EP (1) | EP1793815A4 (enExample) |
| JP (1) | JP2008514722A (enExample) |
| KR (1) | KR20070106680A (enExample) |
| CA (1) | CA2582449A1 (enExample) |
| TW (1) | TW200618795A (enExample) |
| WO (1) | WO2006039441A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009013633A2 (en) * | 2007-07-20 | 2009-01-29 | Actavis Group Ptc Ehf | Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts |
| EP2075246A1 (en) * | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| WO2009090544A2 (en) * | 2008-01-16 | 2009-07-23 | Matrix Laboratories Limited | Process for producing amorphous atorvastatin calcium |
| WO2010066687A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Stabalized statin-comprising compositions |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| WO2013072770A2 (en) | 2011-11-15 | 2013-05-23 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
| WO2014041059A1 (en) * | 2012-09-17 | 2014-03-20 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Process to produce atorvastatin intermediates |
| JPWO2017042995A1 (ja) * | 2015-09-07 | 2018-06-28 | パナソニックＩｐマネジメント株式会社 | 車載用ステレオカメラ装置、およびその補正方法 |
| CN109280024A (zh) * | 2018-10-09 | 2019-01-29 | 河南师范大学 | 一种高纯度阿托伐他汀叔丁酯的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210840A (en) * | 1984-01-18 | 1987-05-29 | Johnson & Johnson Baby Prod | Composition comprising synergistic combination of miconazole nitrate and zinc oxide |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| US6673374B2 (en) * | 1998-07-31 | 2004-01-06 | Howard Murad | Pharmaceutical compositions and methods for managing skin conditions |
| JP2002035579A (ja) * | 2000-07-24 | 2002-02-05 | Mitsubishi Gas Chem Co Inc | 水蒸気を吸収する脱酸素剤組成物 |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| IN190564B (enExample) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| AU2003245736A1 (en) * | 2002-02-14 | 2003-09-04 | Ranbaxy Laboratories Limited | Formulations of atorvastatin stabilized with alkali metal additions |
| IL163594A0 (en) * | 2002-02-19 | 2005-12-18 | Teva Pharma | Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent |
| SI21302A (sl) * | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| TW200513199A (en) * | 2003-08-12 | 2005-04-16 | Mitsubishi Gas Chemical Co | Oxygen absorber composition, oxygen absorber packaging and oxygen absorption method |
| EP1723157B2 (en) * | 2004-02-26 | 2017-02-08 | Zentiva, k.s. | Amorphous forms of risedronate monosodium |
| WO2005090301A1 (en) * | 2004-03-17 | 2005-09-29 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
| DE602004032578D1 (de) * | 2004-03-19 | 2011-06-16 | Vb Medicare Pvt Ltd | Verbessertes verfahren zur herstellung von chlorierter saccharose |
-
2005
- 2005-09-29 JP JP2007534782A patent/JP2008514722A/ja active Pending
- 2005-09-29 WO PCT/US2005/035094 patent/WO2006039441A2/en not_active Ceased
- 2005-09-29 US US11/576,396 patent/US20080009540A1/en not_active Abandoned
- 2005-09-29 EP EP05803604A patent/EP1793815A4/en not_active Withdrawn
- 2005-09-29 CA CA002582449A patent/CA2582449A1/en not_active Abandoned
- 2005-09-29 KR KR1020077007918A patent/KR20070106680A/ko not_active Ceased
- 2005-09-30 TW TW094134218A patent/TW200618795A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080009540A1 (en) | 2008-01-10 |
| WO2006039441A2 (en) | 2006-04-13 |
| EP1793815A4 (en) | 2010-12-29 |
| JP2008514722A (ja) | 2008-05-08 |
| EP1793815A2 (en) | 2007-06-13 |
| CA2582449A1 (en) | 2006-04-13 |
| WO2006039441A3 (en) | 2006-07-20 |
| KR20070106680A (ko) | 2007-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY147435A (en) | Process for the production of atorvastatin calcium in amorphous form | |
| IL173763A0 (en) | Plant growing machine | |
| SI1915349T1 (sl) | Postopek za pripravo čistega amorfnega rosuvastatin kalcija | |
| EP1790635A3 (en) | Processes for preparing amorphous fluvastatin sodium | |
| AU307406S (en) | Packaging | |
| TWI347359B (en) | Methods of inhibiting the adherence of lenses to their packaging | |
| TW200618795A (en) | Amorphous atorvastatin calcium | |
| MXPA04001142A (es) | Sintesis bidireccional de agentes de transporte de oligoguanidina. | |
| HUP0300761A3 (en) | Process for the production of amorphous atorvastatin calcium | |
| PL1776401T3 (pl) | Polimery kationowe zawierające 2-hydroksyetyl-metakrylowy jako promotory zaklejania z wykorzystaniem ASA | |
| WO2006111389A3 (de) | Transparente polyamidfolien | |
| TW200637832A (en) | Process for preparing amorphous valsartan | |
| MX2007004423A (es) | Calcio de rosuvastatina con bajo contenido de sal. | |
| ZA200608632B (en) | Process for forming amorphous atorvastatin calcium | |
| MY127609A (en) | Process for preparing discodermolide and analogues thereof | |
| FI20065595A7 (fi) | Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi | |
| FI20065594A7 (fi) | Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi | |
| TH79580A (th) | อะทอร์วาสแตตินแคลเซียมอสัณฐาน | |
| TW200700474A (en) | Transparente polyamidfolien | |
| TW200637495A (en) | Novel composite for inhibiting algae growth and use thereof | |
| HK1124042A (en) | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors | |
| LT2001122A (en) | Method of propagation by layering | |
| TW564671U (en) | An improved packing sheet for potted plants | |
| FI20022015A0 (fi) | Kuitupohjainen pakkaustäytemuotokappale | |
| HK1098752A (en) | Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols |